All the news Showing 10 of 204 articles from: Finance, funding & health economicsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows Keith Alcorn / 27 July 2017 HIV, hepatitis B and C and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College, London, reported ... Costs for generic hepatitis C drugs available in India would be paid back in 5 to 10 years Massachusetts General Hospital press release / 23 May 2017 France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment Intellectual Property Watch / 03 April 2017 Pharma could take NHS England to court over new delaying tactics PharmaPhorum / 27 March 2017 Industry links with patient organisations BMJ / 27 March 2017 Regulator defends hepatitis charity criticised on BBC show Third Sector / 02 March 2017 Hepatitis C patients 'go abroad for drugs' BBC Radio 4 (audio) / 19 December 2016 Hepatitis C drugs Australia's most expensive, cost taxpayers $1 billion in four months ABC Online / 05 December 2016 New WHO report shows strategic purchasing of medicines can improve access in the European Region World Health Organization / 02 December 2016 Hepatitis C: The State of Medicaid Access National Viral Hepatitis Roundtable / 21 November 2016 ← Prev1...23456...21Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive